If you have searched this question before, you have probably seen four different answers. One site says $299. Another says $449. A third says $1,086. A fourth says $25.
All four are correct. They describe different people.
Tirzepatide has no single price. It has six payment routes, and which one you land on depends on your insurance status, your dose, and — this is the part almost nobody explains — whether you refill on time.
The short answer
| Route | Monthly cost | Who it applies to |
|---|---|---|
| Commercial insurance + savings card | $25 | Covered plans, eligible patients |
| Medicare GLP-1 Bridge | ~$50 | Part D beneficiaries, from July 2026 |
| LillyDirect self-pay, starter dose | $299 | Cash payers, 2.5 mg |
| LillyDirect self-pay, maintenance | $449 | Cash payers, 7.5–15 mg, refilled on time |
| Compounded telehealth | $199–$650 | Cash payers using compounding programs |
| Retail, no assistance | ~$1,086 | People who did not check the above |
That last row is the one worth avoiding. It is also the price most people quote when they say tirzepatide is unaffordable.
Monthly cost by payment route
Commercial plans, eligible patients
Part D, from July 2026
2.5 mg
7.5-15 mg, refilled on time
Top of advertised range
List price
Verified 2026-08-01 against manufacturer and CMS published materials.
The refill rule that changes everything
This is the detail that explains why cost guides contradict each other.
LillyDirect’s Self Pay Journey Program advertises $449 a month for maintenance doses — 7.5 mg, 10 mg, 12.5 mg, and 15 mg. That price is real. It is also conditional.
To keep it, you have to complete your next refill within 45 days of receiving the previous one. Miss the window and you revert to standard pricing:
| Dose | On-time price | Standard price |
|---|---|---|
| 7.5 mg | $449 | $599 |
| 10 mg | $449 | $699 |
| 12.5 mg | $449 | $849 |
| 15 mg | $449 | $1,049 |
What a late refill costs, by dose
On-time price is $449 for every maintenance dose. Amber shows the penalty.
At 15 mg, a late refill more than doubles your bill. And the two starter doses — 2.5 mg at $299 and 5 mg at $399 — carry no such condition, which is why so many people are caught off guard the first time they escalate.
What to do about it: set a calendar reminder for day 35 after each delivery. Not day 44. Processing and shipping take time, and the clock runs from receipt of the previous prescription, not from when you place the order.
Route by route
With commercial insurance
If your plan covers Zepbound for chronic weight management, the Lilly Savings Card can bring your copay down to $25 a month. This is by far the cheapest route and the first thing to check.
The catch is coverage itself. Roughly 60 percent of large commercial employer plans cover branded GLP-1 medication for weight loss, which means four in ten do not. Call the number on your card and ask two specific questions: is Zepbound on the formulary, and does it require prior authorization?
If it requires prior authorization, that is not a refusal — it is paperwork. Providers who handle prior auth on your behalf are worth more than a slightly lower monthly price.
With Medicare
Until recently this was a dead end. Medicare Part D has historically excluded weight-loss drugs by statute.
That changed on 1 July 2026. Under the Medicare GLP-1 Bridge, a time-limited CMS demonstration running through the end of 2027, eligible Part D beneficiaries can access certain GLP-1 medications at roughly $50 for a monthly supply.
If you are on Medicare and were quoted $1,000 last year, the answer today is different. Ask your plan directly about Bridge eligibility.
Paying cash: brand
LillyDirect is Eli Lilly’s direct-to-patient channel, and it sells Zepbound below retail:
- 2.5 mg — $299/month
- 5 mg — $399/month
- 7.5 mg through 15 mg — $449/month with on-time refills
Self-pay cannot be combined with insurance of any kind. If you have coverage, use it; the savings card beats these numbers.
Two changes worth knowing about. In March 2026, Lilly extended self-pay pricing for Zepbound KwikPens to major retail pharmacies nationwide, so LillyDirect is no longer the only cash route. And Mounjaro — the same molecule under its diabetes label — sells at a flat $499 a month for all doses, which makes it worse value than Zepbound at maintenance doses and better value at none.
Paying cash: compounded
Compounded tirzepatide programs advertise between roughly $199 and $650 a month, usually bundled with a consultation and ongoing support.
Three things to understand before comparing that number to $449.
It is not the same product. Compounded tirzepatide is prepared by a compounding pharmacy, not by the original manufacturer. It does not go through the same premarket review for safety, effectiveness, or manufacturing quality, and it is not therapeutically equivalent to the brand.
The regulatory ground is moving. The FDA has issued three large waves of warning letters to telehealth companies marketing compounded GLP-1 products since September 2025, and in 2026 proposed permanently restricting large-scale compounding of tirzepatide and semaglutide. If you are budgeting twelve months out on a compounded program, budget for the possibility that it will not be available for all twelve.
Advertised prices are often entry prices. Check whether the quoted figure holds as your dose escalates, and whether a membership fee sits on top of the medication cost.
Our provider reviews break down what each program charges and what is bundled into that number. For one worked example, see the MEDVi tirzepatide cost breakdown.
Income-based assistance
The Lilly Cares Foundation provides Mounjaro free to qualifying uninsured patients at or below 400 percent of the federal poverty level — about $63,840 for a single-person household in 2026.
There is no equivalent income-based program for Zepbound. If you are uninsured, low-income, and have a type 2 diabetes diagnosis, the Mounjaro pathway is worth raising with your provider.
Tirzepatide versus semaglutide on cost
People ask which is cheaper. On brand-to-brand cash pricing they are close enough that cost should not decide it — the difference between Zepbound and Wegovy self-pay is smaller than the difference between having insurance and not.
On compounded pricing, tirzepatide typically runs higher than semaglutide, often $50 to $150 more per month for a comparable program.
The more useful question is not which molecule is cheaper but which payment route you qualify for. A person with commercial coverage pays $25 for either. A person without coverage pays ten to twenty times that for both.
What most people get wrong
Quoting the list price. The ~$1,086 retail figure describes almost nobody. It is the number that circulates because it is dramatic, not because it is typical.
Comparing compounded prices to brand prices as though they are the same product. They are not, and a price comparison that ignores that is not a price comparison.
Ignoring what is bundled. A $199 program with a separate membership fee and a $449 program with consultations and coaching included are not $250 apart.
Assuming last year’s answer still holds. Zepbound maintenance pricing dropped from $699 to $449 in early 2026. Medicare coverage did not exist before July. Retail pharmacy self-pay arrived in March. This market reprices faster than most guides get updated — including, eventually, this one.
Before you commit
Work through this in order:
- Call your insurer. Ask whether Zepbound is on the formulary and whether it needs prior authorization.
- If you are on Medicare, ask your Part D plan about GLP-1 Bridge eligibility.
- If you are paying cash, price LillyDirect and retail pharmacy self-pay before looking at anything else.
- If you are considering a compounded program, ask which pharmacy prepares it, whether that pharmacy is named publicly, and what the price becomes at maintenance dose. Our provider reviews answer those questions program by program.
- Whatever route you take, put a calendar reminder at day 35 after each delivery.
Prices in this guide were checked on 1 August 2026 against manufacturer and CMS published materials. This is educational information about cost, not medical advice, and whether tirzepatide is appropriate for you is a decision for you and a licensed clinician.
Common questions